Gunnar Sandberg

1

Hälsa

Gunnar [email protected]

2

Main points

The 7th Framework programme (FP7) Rationale and approach Basic principles 3rd call for proposals Funding opportunities Factors for success

3

• Part of the European Commission• 2 Objectives:

– Develop European research policies and strategies in collaboration with EU Member States

– Provide support to research through the ”Framework Programmes”

The Framework Programme (FP) is the European Union’s multi-annual research funding mechanism

What is DG Research

4

Budgets of the EU Framework Programmes1984-2013

NB: Budgets in current prices. Source: Annual Report 2003, plus FP7 revised proposal

0

2000

4000

6000

8000

10000

12000

1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012

Ū million

5

Indicative breakdown (million €)

Total = € 50.4 billion for 7 years(40% increase compared to FP6)

ERC

FP7 (2007-2013)

6

Collaborative research across borders and other barriers

• between countries: – multinational consortia, with at least 3 partners from

27 EU Member States (MS) + Associated Countries (Albania, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey)

– researchers from any country in the world can participate

– However: researchers from highly industrialised countries outside Europe can rarely receive funding (i.e Australia, Canada, Japan, Korea, New-Zealand, USA)

• between different types of organizations– Public & private sector: universities, research centres, large

companies, small and medium-size enterprises (SMEs), etc. disciplines: multidisciplinary, translational research

8

Main policy drivers in the Health theme

Improving health of European citizens

Increasing competitiveness of European health-related industries and businesses

Addressing global health issues, e.g. emerging epidemics

Budget: €6.1 billion (19%) over 7 years (2007-2013)

Both basic and applied research is supported

9

Submission & evaluation

Basic principles:

annual calls for proposals

eligibility check (partners, budgets, scope, deadline)

evaluation by panels of independent experts

3 Evaluation criteria: Science & Technology excellence Implementation & Management Dissemination & Impact

feedback: evaluation summary report (ESR).

negotiation: grant agreement, funding for 2-5 y.

10

Funding schemes in the Health theme (3rd call)

Funding schemes lower limits upper limit min. partners

Collaborative Projects (CP):

Large-scale (CP-IP) €6m €12m ≥3

Medium-scale €3m €6m ≥3

Small-scale (CP-FP) up to €3m ≥3

Network of Excellence (NoE) up to €12m ≥3

Coordination action (CA) up to €1.5m ≥3

Support action (SA) up to €0.5m ≥1

NB: the limits for minimum and maximum requested EC grant and for the minimum number of partners are eligibility criteria !

11

the Health theme:structure and content

pillar 1:Biotechnology, generic tools

& technologies for health

pillar 2:Translating research for

human health

pillar 3:Optimising the delivery

of health care

cross-cutting issues: child health, the health of ageing population gender-related health issues

Activity (pillar) 4: Other actions across the theme

12

3rd call for proposals for the Health theme

Publication of 3rd call expected: 3 September 2008 drawing on the budget for 2009: ~€ 591m

there will in fact be two calls, published in parallel:

‘FP7-HEALTH-2009-single-stage’ €476 m for most areas of the work programme expected deadline: 3 Dec. 2008

‘FP7-HEALTH-2009-two-stage’ €115 m only for areas 1.1 & 2.1. expected deadlines for 1st stage: 3 Dec. 2008

indicative deadline for 2nd stage 22 April 2009

Based on proposals of European Commission services, subject to confirmation in call text.

13

Introducing two-stage

submission/evaluation Only for areas 1.1 & 2.1

1.1 – High-throughput research

2.1 – Integrating biological data and processes (large-scale

data-gathering and systems biology)

First stage: proposal size limited to 8 pages

Evaluation of 2 criteria only (S/T quality and Impact)

Second stage: only coordinators of proposals passing Stage 1 will be

invited to submit full proposals for Stage 2

evaluation on all 3 criteria, independently from Stage 1.

14

Two-stage evaluation: Topics

Area 1.1 High-throughput research

• Computational tools for genome annotation and genotype/ phenotype data integration.

• High throughput tools and technologies to analyse samples in large-scale human biobanks.

• Tools & technologies for characterisation of protein functions.

Area 2.1 Large-scale data gathering & Systems biology

• Large-scale functional genomics effort in multi-cellular organisms to elucidate the function of human genes products.

• Large-scale functional genomics efforts to identify molecular determinants of cancer.

• Characterisation of human genetic variation in Europe.

• Systems biology approaches for basic biological processes

relevant to health and disease.

15

Collaborative Health Research:

Pillar 1

1: Biotechnology, generic tools and technologies

High-throughput research – only 2-stage in 3rd call

Detection, diagnosis and monitoring

Predicting suitability, safety and efficacy of therapies – mainly implemented through Innovative Medicines Initiative (IMI)

Innovative therapeutic approaches and interventions

16

1.2 Detection, diagnosis and monitoring (1)

Topics proposed for 3rd call:

• Development of tools for sensitive and specific detection of proteins and their interactions for diagnostic purposes. Funding scheme: CP-FP, max. € 6m. (1 or more projects)

• Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders. Funding scheme: CP-FP, max. € 3m (1 or more projects)

• Novel MR-compatible PET detectors for simultaneous PET/MRI imaging. Funding scheme: CP-IP, max. € 12m. (max. 1 project)

17

1.2 Detection, diagnosis and monitoring (2)


• Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy. Funding scheme: CP-FP, max. € 6m. (max. 1 project)

• Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases. Funding scheme: CP-FP, max. € 6m. (1 or more projects)

• Evaluation of the potential health impact of diagnostic imaging agents doses (…with a focus on either radioactive or non-radioactive imaging agents).Funding scheme: Support Action, max. € 0.5m. (max. 1 project for each area)

18

1.4 Innovative therapeutic approaches and interventions


Regenerative medicine• Cell therapy for tissue and organs. Funding scheme: CP-IP, max. € 12m.

• Regeneration of tissue using bio-compatible materials & cells. Funding scheme: CP-IP, max. € 12m.

• Activation of endogenous cells as an approach to regenerative medicine. Funding scheme: CP-IP, max. € 12m.

For these topics, which are all for large-scale integrating projects, more than one project may be funded per topic, provided they are of sufficient quality and depending on the EC budget available.

19

Collaborative Health Research

Pillar 2

2: Translating research for human health

Integrating biological data and processes – only 2-stage in 3rd call

Research on the brain and related diseases, human development and ageing

Translational research in major infectious diseases

Translational research in other major diseases

20

2.2 – Research on Brain diseases

human development and ageing

Topics in the 3rd call:

• Synaptopathies: genesis, mechanisms and therapy. Funding scheme: CP-IP, max. € 12m. (max. 1 project)

• Identifying genetic and environmental interactions in schizophrenia. Funding scheme: CP-IP max. € 12m. (max. 1 project)

• Optimising current therapeutic approaches to schizophrenia.Funding scheme: CP-IP, max. € 12m (max. 1 project)

• Understanding the blood brain barrier to improve drug delivery to the brain.

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

• Psycho-social factors of brain disorders. Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)

• NO TOPICS on Human Development and Ageing in 3rd call

21

2.3.1 – Infectious Diseases:Anti-microbial drug resistance


• Global collaborative research on the prevention of antibiotic resistance. Funding scheme: CP-IP, max. € 12m. (max. 1 project)

• Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host. Funding scheme: CP-FP, max. € 6m. (1 or more projects)

• Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers. Funding scheme: CP-FP, max. € 6m. (1 or more projects)

22

2.3.2 – Infectious Diseases:HIV/AIDS, malaria & TB


• Integration of European efforts in research on malaria.

Funding scheme: Network of Excellence, max. € 12m. (max. 1 project)

• Identification and pre-clinical testing of new vaccine candidates for tuberculosis. Funding scheme: CP-IP, max. € 12m. (max. 1 project)

• Discovery and/or development of new and promising anti-HIV microbicides. Funding scheme: CP-IP, max. € 12m. (max. 1 project)

• Mucosal and topical vaccines for poverty related diseases (HIV/AIDS, malaria and/or TB). Funding scheme: CP-IP, max. € 12m. (max. 1 project)

• Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB). Funding scheme: CP-FP, max. € 3m. (max. 1 project)

23

2.3.3 – Potentially new and re-merging epidemics

Topic proposed for 3rd call:

• Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission. Funding scheme: CP-FP, max. € 3m. (max. 1 project)

24

2.3.4 Neglected infectious diseases

Topics proposed for 3rd call: published under area 4.3.1

• Discovery and development of new vaccines or drugs for helminth infections (SICA). Target region: ICPC. Funding scheme: CP-FP max. € 6m. (1 or more projects)

• Identification and development of vaccine candidates for neglected bacterial infections (SICA). Target region: ICPC.

Funding scheme: CP-FP max. € 6m. (1 or more projects)

• Human Immune Responses to co-infections of Poverty-Related (HIV, malaria, TB) and Neglected Infectious Diseases (SICA). Target region: ACP. Funding scheme: CP-IP, max. € 12m. (max 1 project)

SICA: Specific International Cooperation ActionICPC: International Cooperation Partner CountriesACP: African, Caribbean and Pacific countries

25

2.4.1 – Cancer

Temporary closure of this area

No topics in this call.

26

2.4.2 – Cardiovascular disease


• Improved or new therapeutic approaches for the treatment of heart failure. Funding scheme: CP-IP, max. € 12m. (max 1 project)

• Cardiac arrhythmias: from genes to improved management of patients. Funding scheme: CP-IP, max. € 12m. (max 1 project)

• Translation of basic knowledge on inherited cardiomyopathies into clinical practice. Funding scheme: CP-FP, max. € 3m. (1 or more projects)

27

2.4.3 – Diabetes and obesity


• Novel therapeutical approach to pregnancy-induced diabetes. Funding scheme: CP-FP, max. € 3m. (max. 1 project)

• Novel immunotherapies for type 1 diabetes. Funding scheme: CP-IP, max. € 12m. (max. 1 project)

• Molecular pathways in food intake at CNS-liver-gut regulation level. Funding scheme: CP-FP, max. € 3m. (max. 1 project)

28

Rare Diseases and Other Chronic Diseases

Topics for 2.4.4 – Rare Diseases:

• Rare neurological diseases. Funding scheme: CP-FP, max. € 6m. (1 or more projects)

• Preclinical development of substances with a clear potential as orphan drugs. Funding scheme: CP-FP, max. € 3m. (1 or more projects)

Topics for 2.4.5 – Other chronic diseases:

• Prevention and treatment of non-alcoholic fatty liver disease . Funding scheme: CP-FP, max. €6m. (1 or more projects)

• Cellular and molecular mechanisms of development of chronic kidney disease (CKD). Funding scheme: CP-IP, max. € 12m. (max. 1 project)

29

3: Optimising the delivery of healthcare

Translating clinical research into clinical practice

Quality, efficiency and solidarity of healthcare systems

Enhanced health promotion and disease prevention

Collaborative Health Research:

Pillar 3

30

Collaborative researchon the Health theme

4. Actions across the Theme

Coordination & Support Actions across the theme

Responding to EU policy needs

Specific International Cooperation Actions (SICA)

31

4.1 Coordination and support actions across the theme


• Monitoring tool and technology transfer analysis for Health theme grants during FP7. Funding scheme: Support Action, max. € 1m. (max. 1 project)

• Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers. Funding scheme: Coordination or Support Action, max. € 1m (1 or more projects)

• Targeting publication bias. Funding scheme: Support Action, max. € 0.5m. (max. 1 project)

32

4.2 Responding to EU policy needs


• Adapting off-patent medicines to the specific needs of paediatric populations. Funding scheme: CP-FP, max. € 6m. (1 or more projects)

• Study of the arrhythmogenic potential of different classes of medicines. Funding scheme: CP-FP, max. € 3m. (1 or more projects)

• Human papillomavirus vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease modelling and health economics. Funding scheme: CP-FP, max. € 3m. (max. 1 project)

• Coordinating action on organ procurement & transplantation with a focus on new EU Member States. Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)

33

4.3 SICA Specific International Cooperation

ActionsTopics proposed for 3rd call:

• Strategies for improving reproductive health. Target region: ICPC*. Funding scheme: CP-FP, max. € 3m. (1 or more projects)

• Access to medicines. Target region: ICPC*. Funding scheme: CP-FP, max. € 3m. (1 or more projects)

• Integration of disease surveillance and health systems response. Target region: ACP** or Asian countries. Funding scheme: CP-FP, max. € 3m. (1 or more projects)

• Comparative population genetic studies on multifactorial diseases. Target region: Russia. Funding scheme: CP-FP, max. € 3m. (1 project)

• Diabetic and weight-related co-morbidity in heart failure. Target region: Russia. Funding scheme: CP-FP, max. € 3m. (max. 1 project)*ICPC: International Cooperation Partner Countries

**ACP: African, Caribbean and Pacific countries

34

Key figures from last call

call: 2007-B (18 Sept. 2007)

budget: € 567 million (2008) proposals received: 902 proposals evaluated: 865 (ineligible 37) proposals to be funded: 167 % of proposals evaluated: 19%

av. grant per participant: €334,000

Success rate: Sweden- 26% (vs Germany- 22%; Denmark- 28%)

35

Other opportunities in FP7

Mainly through Collaborative Research, but also:

• Innovative Medicines Initiative (IMI) – Joint public-private initiative between

EFPIA and EC

• European Research Council (ERC)– Grants to individual research groups

• People Programme (Marie-Curie)– Individual fellowships

36

2 Billion EURO

1 Billion Euro1 Billion Euro

Public PrivatePartnership

IMI is a public-private partnership

Aim: To remove major bottlenecks and to provide with new “toolbox” to make the drug development process safer and more efficient.

(1) re-invigorate the European bio-pharmaceutical sector

(2) delivery of new approaches, tools, methods and technologies, improve knowledge management of research results and data, and support the training of professionals

37

• Individual teams led by independent Principal Investigators are supported

• Frontier Research Project: All fields of research are eligible

• Peer Review Evaluation: Scientific excellence is the sole selection criterion (25 panels – 9 for LifeSciences)

• 2 basic grant forms:• ERC Starting Independent Research Grant (2-9 years post PhD):

up to € 2 million for 5 years. Deadline: Autumn 2008• ERC Advanced Investigator Grant: up to € 2.5 (3.5) million for 5

years. Deadline (LifeSciences): 22 April 2008

Ideas Programme (European Research Council)

38

• MC Initial Training Networks: • Participants: Network of at least 3 (universities, research centres,

companies, SMEs), • Funding for: recruitment of early-stage researchers, visiting

scholars, networking

• Life-long training and career development (individual fellowships for experienced researchers/postdocs)

• Intra-European Fellowships for Career development (IEF), 12-24 months

• European Reintegration grants (ERG), following a MC mobility action

• Co-funding of Regional, National, and International Programmes (COFUND)

People Programme (Marie Curie) (1)

39

• Industry-academia partnerships and pathways (IAPP): • Participants: at least one academic and one industry/SME

organisation from at least 2 different MS/AC • Funding for: exchange of know-how + experience through

secondments, visiting scholars/trainers from outside partnership, networking (for 3-4 years)

• Conference in Brussels on 14 Jan 2008: ftp://ftp.cordis.europa.eu/pub/fp7/people/docs/marie-curie-iapp-conference-140108_en.doc

• International Dimension (individual fellowships for experienced researchers/postdocs)

• International outgoing fellowships for career development (IOF)• International incoming fellowships (IIF)• MC international reintegration grants (IRG)

People Programme (Marie Curie) (2)

40

Priority setting – how are topics decided?

1) Conferences, workshops, reflection papers

2) Dedicated expert workshops

3) Important stakeholder organisations (WHO, ECDC)

4) Advisory Group (experts)

5) Commission services (support to EU policies)

6) Programme Committee (Member States)

41

Dan AndréeSpecial AdvisorMinistry of Education and Research

“A rough guide to the FP7 Work Programmes. Who can be involved in the preparation? What to do, when and how?”

Available at http://www.vinnova.se

42

Information

• Partnersökning; SMEsGo Health www.smesgohealth.org

• Planeringsbidrag och SMINTwww.vinnova.se

• Utlysningstext, EPSS etcwww.cordis.lu

43

Hälsa

Resultat

44

Första utlysningen

Ansökningar totalt: 894

with Swedish participation: 231

with Swedish SME: 43

Prioriterade: 152


with Swedish coordinator: 10 with Swedish SME: 11

45

Andra utlysningen prel efter start av SME Support Office

Ansökningar totalt: 897 with Swedish participation: nd

with Swedish SME: 58

Prioriterade: 172


with Swedish coordinator: 11 with Swedish SME: 15

46

Thank you

47

Advantages of EC Research Projects

• Networking with others– Access to large pool of know-how within the consortium

• Financial benefit – Contribution from EC– Few strings attached

• Quality stamp – Tough selection procedure– Leverage for additional funding

48

Risks of joining EC Research Projects

• Competition– Competition is tough – the proposal and partners must

be excellent

• Partnership principle– Ownership and decision in partnership

• Bureaucracy– Paper work and guidelines (But maybe not that bad)

• Financial risk – Co-funding required (25-50%)– Cash-flow problems (pre/post-payments and delays)

49

The Evaluation process

EligibilityFinal decision

and procedures

PanelSubmissionConsensus

meeting in Brussels

Remote individual evaluation

Finalisation

COMMISSIONCOMMISSIONEXPERTSEXPERTS

Evaluation

50

1) Start well in advance

2) Be clear of what you want and what is requested in the call: if the two do not fit, do not bother… (it shows!)

3) Make sure the proposal addresses the call text fully (topic and overall objective of the area – read the workprogramme introduction!)

4) Think European (what added value will this proposal bring to Europe?)

5) Where do I find those SMEs? (SMEsgoHealth)

6) Geographical balance… (truths and myths)

7) Make sure your partners are fully committed to the project (and not only to obtaining financial support to continue doing what they always did)

8) Contact your NCP / University EU Liaison office to learn from their experience, get tips and the latest news

Strategic Planning (I)

51

1) Download and READ the relevant documents before you start to write:

• Workprogramme (including introduction and annexes)• Guide for proposers

2) Be aware of eligibility criteria:• Proposal submitted on time (before 17:00 the day of

the dead-line, NOT 17:01!!) with margins –there may be unforeseen technical problems

• Respect the budget brackets for the funding scheme (1 € outside the range – above or below! - and the proposal will not even be evaluated!)

• Minimum (number) legal participants• Don‘t mix single and 2 stage topics, where applicable

Strategic Planning (II)

52

1) Be clear on the evaluation criteria and thresholds*

2) Section A – Formalities (try to be accurate!)

3) Section B – The actual proposal text (evaluation criterion Relevance of FP6 is now incorporated into Science)

• B1- Science 3*/5 – 33%• B2 – Implementation 3*/5 - 33%• B3 – Impact 3*/5 - 33%• Overall – 10*/15

*may change from call to call….

Strategic Planning (III)

53

Importance of the IMPACT section as a proposal differentiator

• A typical proposal from academics will have:

• 60 pages of wonderful science• 12 pages of wonderful colleagues and

management• 2 pages of IMPACT – mostly repeating the

introduction of B1 saying:– X million people suffer from this disease– We will create a vaccine…

54

What should the IMPACT section be about?

• What will really happen if the project is successful e.g. The new vaccine:– Somebody has to pay for Phase II, II and IV clinical

trials – where will that money come from?– What regulatory hurdles must be overcome – who will

overcome them? – Will the new vaccine be licensed to a large enterprise

pharma (preferably one in your consortium) that will provide a route to market?

– How will you convince pharma to take your vaccine?• What competition is already out there?• What differentiates your vaccine from all the others?

55

How to describe the steps needed to meet the Expected Targets

• What would you do in the ‘real world’ to achieve those targets? = exploitation and dissemination

• Say that you will start E&D activities right from the Kick-Off Meeting (c.f. the vaccine example earlier)

• Dissemination:– to whom?– at what conferences?– in what workshops?– over the internet?– in a new or extended partnership?

56

Handling intellectual property issues in the proposal and in the post-project

world• Intellectual property (IP) is not just patents – but what

is it?• Tell the evaluators so that they know you know• Distinguish background and foreground IP• Tell the evaluators what foreground IP you think will

be created in the project• Tell them how you will protect it• Tell them how you will use it to get your e.g. vaccine,

to market

Gunnar Sandberg

Documents

Transcript of Gunnar Sandberg